(Q38843479)

6 September 2017

1 reference

title

Monoclonal Antibodies for Lipid Management (English)

1 reference

6 September 2017

1 reference

Matthew J Feinstein

1

0 references

Donald Lloyd-Jones

object named as

Donald M Lloyd-Jones

series ordinal

2

0 references

publication date

1 July 2016

1 reference

Current Atherosclerosis Reports

6 September 2017

published in

1 reference

6 September 2017

volume

18

1 reference

6 September 2017

issue

7

1 reference

6 September 2017

page(s)

39

1 reference

Factors of risk in the development of coronary heart disease--six year follow-up experience. The Framingham Study

6 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Epidemiological studies of CHD and the evolution of preventive cardiology

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Lipids, diabetes, and coronary heart disease: insights from the Framingham Study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: The Strong Heart Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effects of torcetrapib in patients at high risk for coronary events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effects of combination lipid therapy in type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effects of extended-release niacin with laropiprant in high-risk patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effects of dalcetrapib in patients with a recent acute coronary syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Reduction in Total Cardiovascular Events With Ezetimibe/Simvastatin Post-Acute Coronary Syndrome: The IMPROVE-IT Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Mutations in PCSK9 cause autosomal dominant hypercholesterolemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Molecular biology of PCSK9: its role in LDL metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Apolipoprotein B100 metabolism in autosomal-dominant hypercholesterolemia related to mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Evidence for effect of mutant PCSK9 on apolipoprotein B secretion as the cause of unusually severe dominant hypercholesterolaemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

NARC-1/PCSK9 and its natural mutants: zymogen cleavage and effects on the low density lipoprotein (LDL) receptor and LDL cholesterol

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Adenoviral-mediated expression of Pcsk9 in mice results in a low-density lipoprotein receptor knockout phenotype

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Post-transcriptional regulation of low density lipoprotein receptor protein by proprotein convertase subtilisin/kexin type 9a in mouse liver.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

The secretory proprotein convertase neural apoptosis-regulated convertase 1 (NARC-1): liver regeneration and neuronal differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: the Coronary Artery Risk Development in Young Adults Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Sequence variations in PCSK9, low LDL, and protection against coronary heart disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Dissection of the endogenous cellular pathways of PCSK9-induced low density lipoprotein receptor degradation: evidence for an intracellular route

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

The biology and therapeutic targeting of the proprotein convertases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Targeting the proprotein convertase subtilisin/kexin type 9 for the treatment of dyslipidemia and atherosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effect of a monoclonal antibody to PCSK9, REGN727/SAR236553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: a phase 2 randomised con

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): a randomised, placebo-controlled, dose-ranging, phase

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 In

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: the GAUSS randomized trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of alirocumab in high cardiovascular risk patients with inadequately controlled hypercholesterolaemia on maximally tolerated doses of statins: the ODYSSEY COMBO II randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of alirocumab in patients with heterozygous familial hypercholesterolemia not adequately controlled with current lipid-lowering therapy: design and rationale of the ODYSSEY FH studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of alirocumab as add-on therapy in high-cardiovascular-risk patients with hypercholesterolemia not adequately controlled with atorvastatin (20 or 40 mg) or rosuvastatin (10 or 20 mg): design and rationale of the ODYSSEY OPTIONS S

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of alirocumab in reducing lipids and cardiovascular events

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

A 52-week placebo-controlled trial of evolocumab in hyperlipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of longer-term administration of evolocumab (AMG 145) in patients with hypercholesterolemia: 52-week results from the Open-Label Study of Long-Term Evaluation Against LDL-C (OSLER) randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2): a randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Anti-PCSK9 antibody effectively lowers cholesterol in patients with statin intolerance: the GAUSS-2 randomized, placebo-controlled phase 3 clinical trial of evolocumab.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of evolocumab in reducing lipids and cardiovascular events.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Statin-associated adverse cognitive effects: survey results from 171 patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Statins and cognition: a systematic review and meta-analysis of short- and long-term cognitive effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Statins and cognitive function: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Do statins impair cognition? A systematic review and meta-analysis of randomized controlled trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Cochrane review on 'Statins for the treatment of dementia'.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Optimal low-density lipoprotein is 50 to 70 mg/dl: lower is better and physiologically normal

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Cardiovascular disease resulting from a diet and lifestyle at odds with our Paleolithic genome: how to become a 21st-century hunter-gatherer

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

Efficacy and safety of the proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab among high cardiovascular risk patients on maximally tolerated statin therapy: The ODYSSEY COMBO I study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS11883-016-0593-2

2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of Atherosclerotic Cardiovascular Disease Risk: A Report of the American College of Cardiology T

21 January 2018

1 reference

12 December 2020

Inhibition of PCSK9 with evolocumab in homozygous familial hypercholesterolaemia (TESLA Part B): a randomised, double-blind, placebo-controlled trial

1 reference

12 December 2020

Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 as monotherapy in patients with hypercholesterolaemia (MENDEL): a randomised, double-blind, placebo-controlled, phase 2 study

1 reference

12 December 2020

The Environment and Disease: Association or Causation?

1 reference

12 December 2020

Atorvastatin with or without an antibody to PCSK9 in primary hypercholesterolemia

1 reference

12 December 2020

PCSK9: a convertase that coordinates LDL catabolism

1 reference

12 December 2020

Blood-brain barrier permeability is markedly decreased in cholestasis in the rat.

1 reference

12 December 2020

Efficacy and safety of alirocumab vs ezetimibe in statin-intolerant patients, with a statin rechallenge arm: The ODYSSEY ALTERNATIVE randomized trial

1 reference

12 December 2020

10.1007/S11883-016-0593-2

Identifiers

DOI

1 reference

Dimensions Publication ID

6 September 2017

1026930019

0 references

1 reference